These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1205 related articles for article (PubMed ID: 14530780)
1. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Antoniadou A; Torres HA; Lewis RE; Thornby J; Bodey GP; Tarrand JP; Han XY; Rolston KV; Safdar A; Raad II; Kontoyiannis DP Medicine (Baltimore); 2003 Sep; 82(5):309-21. PubMed ID: 14530780 [TBL] [Abstract][Full Text] [Related]
2. Candida and candidaemia. Susceptibility and epidemiology. Arendrup MC Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246 [TBL] [Abstract][Full Text] [Related]
3. Risk factors for candidemia-related mortality at a medical center in central Taiwan. Cheng YR; Lin LC; Young TG; Liu CE; Chen CH; Tsay RW J Microbiol Immunol Infect; 2006 Apr; 39(2):155-61. PubMed ID: 16604249 [TBL] [Abstract][Full Text] [Related]
4. Species distribution, antifungal susceptibility and clonal relatedness of Candida isolates from patients in neonatal and pediatric intensive care units at a medical center in Turkey. Kuzucu C; Durmaz R; Otlu B; Aktas E; Gulcan H; Cizmeci Z New Microbiol; 2008 Jul; 31(3):401-8. PubMed ID: 18843896 [TBL] [Abstract][Full Text] [Related]
5. Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999. Cheng MF; Yu KW; Tang RB; Fan YH; Yang YL; Hsieh KS; Ho M; Lo HJ Diagn Microbiol Infect Dis; 2004 Jan; 48(1):33-7. PubMed ID: 14761719 [TBL] [Abstract][Full Text] [Related]
6. In vitro susceptibility of yeasts isolated from patients in intensive care units to fluconazole and amphotericin B during a 3-year period. Kucukates E; Erturan Z; Susever S; Yegenoglu Y APMIS; 2005 Apr; 113(4):278-83. PubMed ID: 15865609 [TBL] [Abstract][Full Text] [Related]
7. In vitro susceptibility of oral Candida to seven antifungal agents. Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594 [TBL] [Abstract][Full Text] [Related]
9. In vitro susceptibility of 115 isolates of Candida to amphotericin B, fluconazole and itraconazole. Mallié M; Bastide JM Drugs Exp Clin Res; 1996; 22(6):301-7. PubMed ID: 9034756 [TBL] [Abstract][Full Text] [Related]
10. Antifungal susceptibility testing and the correlation with clinical outcome in neonatal candidemia. Huang YC; Kao HT; Lin TY; Kuo AJ Am J Perinatol; 2001 May; 18(3):141-6. PubMed ID: 11414524 [TBL] [Abstract][Full Text] [Related]
11. [Neonatal Candida infections and the antifungal susceptibilities of the related Candida species]. Altuncu E; Bilgen H; Cerikçioğlu N; Ilki A; Ulger N; Bakır M; Akman I; Ozek E Mikrobiyol Bul; 2010 Oct; 44(4):593-603. PubMed ID: 21063972 [TBL] [Abstract][Full Text] [Related]
12. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study). Swinne D; Watelle M; Van der Flaes M; Nolard N Mycoses; 2004 Jun; 47(5-6):177-83. PubMed ID: 15189180 [TBL] [Abstract][Full Text] [Related]
13. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Leroy O; Gangneux JP; Montravers P; Mira JP; Gouin F; Sollet JP; Carlet J; Reynes J; Rosenheim M; Regnier B; Lortholary O; Crit Care Med; 2009 May; 37(5):1612-8. PubMed ID: 19325476 [TBL] [Abstract][Full Text] [Related]
14. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039 [TBL] [Abstract][Full Text] [Related]
15. Emergence of non-albicans Candida species and antifungal resistance in a tertiary care hospital. Capoor MR; Nair D; Deb M; Verma PK; Srivastava L; Aggarwal P Jpn J Infect Dis; 2005 Dec; 58(6):344-8. PubMed ID: 16377864 [TBL] [Abstract][Full Text] [Related]
16. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies. Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613 [TBL] [Abstract][Full Text] [Related]
17. [Biofilm production and antifungal susceptibility patterns of Candida species]. Yücesoy M; Karaman M Mikrobiyol Bul; 2004; 38(1-2):91-8. PubMed ID: 15293907 [TBL] [Abstract][Full Text] [Related]
18. Antifungal susceptibility of epigallocatechin 3-O-gallate (EGCg) on clinical isolates of pathogenic yeasts. Park BJ; Park JC; Taguchi H; Fukushima K; Hyon SH; Takatori K Biochem Biophys Res Commun; 2006 Aug; 347(2):401-5. PubMed ID: 16831406 [TBL] [Abstract][Full Text] [Related]
19. [Multicenter study of fungemia due to yeasts in Argentina]. Rodero L; Davel G; Soria M; Vivot W; Córdoba S; Canteros CE; Saporiti A; Rev Argent Microbiol; 2005; 37(4):189-95. PubMed ID: 16502638 [TBL] [Abstract][Full Text] [Related]
20. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Horn DL; Neofytos D; Anaissie EJ; Fishman JA; Steinbach WJ; Olyaei AJ; Marr KA; Pfaller MA; Chang CH; Webster KM Clin Infect Dis; 2009 Jun; 48(12):1695-703. PubMed ID: 19441981 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]